A method for determining the likelihood of a patient being responsive to cancer immunotherapy
AssigneeUniversitäT ZüRich
InventorsBernd BODENMILLER, Johanna WAGNER, Stephane CHEVRIER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for determining the likelihood of a patient being responsive to cancer immunotherapy by determining the amount of T cells expressing the markers PD-1, CTLA-4, TIM-3, and CD38 and the amount of regulatory T cells (T-regs).
Claims12
A method of determining a likelihood of a patient being responsive to cancer immunotherapy, the cancer immunotherapy comprising administration of a checkpoint modulator agent, wherein the patient has been diagnosed with
- a. estrogen receptor positive cancer or with
- b. breast cancer,
- wherein the method comprises the steps of
- identifying immune cells from a tumor sample obtained from said patient;
- determining the number of immune cells expressing a combination of markers selected from PD-1, CTLA-4, CD38, CD45, CD3, CD25, TIM-3, FOXP3, CD4, and CD8;
- assigning a high likelihood of the patient being responsive to cancer immunotherapy if at least one ratio is above a threshold.
A system for the identification of a patient responsive to cancer immunotherapy, said system being capable of identifying immune cells from a tumor sample obtained from a patient and determining the number of immune cells expressing a combination of markers selected from PD-1, CTLA-4, CD38, CD45, CD3, CD25, TIM-3, FOXP3, CD4, and CD8.
Dependencies are inferred from the claim text.